Budi Hendrik Setia, Younus Laith A, Lafta Methaq Hadi, Parveen Sameena, Mohammad Hawraa Jabbar, Al-Qaim Zahraa Haleem, Jawad Mohammed Abed, Parra Rosario Mireya Romero, Mustafa Yasser Fakri, Alhachami Firas Rahi, Karampoor Sajad, Mirzaei Rasoul
Department of Oral Biology, Dental Pharmacology, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia.
Department of Clinical Laboratory Sciences, Faculty of Pharmacy, Jabir Ibn, Hayyan Medical University, Al Najaf Al Ashraf, Iraq.
Front Oncol. 2023 Jan 19;12:1067974. doi: 10.3389/fonc.2022.1067974. eCollection 2022.
A growing body of evidence has revealed that microRNA (miRNA) expression is dysregulated in cancer, and they can act as either oncogenes or suppressors under certain conditions. Furthermore, some studies have discovered that miRNAs play a role in cancer cell drug resistance by targeting drug-resistance-related genes or influencing genes involved in cell proliferation, cell cycle, and apoptosis. In this regard, the abnormal expression of miRNA-128 (miR-128) has been found in various human malignancies, and its verified target genes are essential in cancer-related processes, including apoptosis, cell propagation, and differentiation. This review will discuss the functions and processes of miR-128 in multiple cancer types. Furthermore, the possible involvement of miR-128 in cancer drug resistance and tumor immunotherapeutic will be addressed.
越来越多的证据表明，微小RNA（miRNA）的表达在癌症中失调，并且在某些情况下它们可以作为癌基因或抑癌基因发挥作用。此外，一些研究发现，miRNA通过靶向耐药相关基因或影响参与细胞增殖、细胞周期和凋亡的基因，在癌细胞耐药中发挥作用。在这方面，已在多种人类恶性肿瘤中发现miRNA-128（miR-128）的异常表达，其已证实的靶基因在包括凋亡、细胞增殖和分化在内的癌症相关过程中至关重要。本综述将讨论miR-128在多种癌症类型中的功能和作用过程。此外，还将探讨miR-128在癌症耐药和肿瘤免疫治疗中的可能作用。
